Med-arb combines two processes in sequence: the parties first attempt mediation, and any issues that remain unresolved automatically proceed to binding arbitration. The same neutral can serve both roles, or the parties can bring in a different arbitrator for the second phase — using the same neutral raises due-process and impartiality concerns, since that person may have learned confidential settlement positions during mediation before becoming the binding decision-maker.

The tradeoff is real: med-arb preserves the collaborative, interest-based benefits of mediation while guaranteeing finality if the talks stall, but critics note that parties may negotiate less candidly during the mediation phase precisely because they know the mediator could later become the arbitrator deciding the case on the merits.

Juricratic models med-arb as a two-stage branch, treating the mediation-phase settlement probability and the arbitration-phase outcome distribution as sequential, conditionally dependent dials rather than collapsing the whole process into a single blended settlement-value estimate.

Commercial parties in an ongoing relationship, such as joint venture partners, choose med-arb to preserve that relationship through good-faith negotiation while still guaranteeing a binding, final resolution if the negotiation phase fails.